Indegene Limited announced its financial results for the third quarter of fiscal year 2026, ending December 31, 2025. The company reported a significant year-over-year revenue growth of 30.8%, reaching ₹9,421 million (approximately $106.1 million). This quarter marked a key milestone as Indegene achieved its first-ever quarterly revenue exceeding $100 million. Profitability remained strong with an adjusted EBITDA of ₹1,747 million, an increase of 15.7% year-over-year and 19.6% sequentially. The adjusted EBITDA margin stood at 18.5%, showing an expansion of 30 basis points from the previous quarter. The company also highlighted several achievements, including revenue per employee crossing $70,000, which it claims is the highest in the industry, and three of its top five customers expanding their annual revenue with Indegene to over $25 million each. Furthermore, 52 customers now generate over $1 million in annual revenue. Indegene secured significant new deals, including two customer contracts with over $10 million in Annual Contract Value (ACV) each, and another exceeding $5 million ACV ($20 million Total Contract Value). The company also completed the strategic acquisitions of BioPharm, a US-based life sciences omnichannel business, and Warn & Co., a UK-based consulting firm, to enhance its domain expertise and capabilities. Indegene's cash and investments remain healthy at ₹13,954 million, net of acquisition outflows, with continued cash generation strengthening its balance sheet. The reported Profit After Tax (PAT) was ₹1,026 million, which the CFO noted was impacted by one-time expenses and higher non-cash amortization, expecting profitability to strengthen as integration synergies are realized.
